Bioengineered human myobundles mimic clinical responses of skeletal muscle to drugs

eLife

Volumn 2015, Issue 4, 2015, Pages

  Madden, Lauran ^a   Juhas, Mark ^a   Kraus, William E ^b   Truskey, George A ^a   Bursac, Nenad ^a  

^a Duke University   (United States)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Contractile force; Drug testing; Human skeletal muscle; Muscle physiology; Tissue engineering

Indexed keywords

ALPHA ACTININ; CALCIUM CHANNEL; CERIVASTATIN; CHLOROQUINE; CHOLINERGIC RECEPTOR; CLENBUTEROL; MEVINOLIN; MYOGENIN; MYOSIN HEAVY CHAIN; TUBOCURARINE CHLORIDE; ACETYLCHOLINE; CAFFEINE; CALCIUM;

ARTICLE; CELL GROWTH; CONTRACTILE FORCE; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMAGING; IMMUNOHISTOCHEMISTRY; MUSCLE CONTRACTION; MUSCLE TISSUE; MYOBUNDLE; PROTEIN EXPRESSION; SKELETAL MUSCLE; STIMULUS; TISSUE ENGINEERING; WESTERN BLOTTING; BIOENGINEERING; BIOMECHANICS; CALCIUM SIGNALING; DRUG EFFECTS; METABOLISM; PHYSIOLOGY; PROCEDURES; REPORTER GENE; REPRODUCIBILITY;

ACETYLCHOLINE; BIOENGINEERING; BIOMECHANICAL PHENOMENA; CAFFEINE; CALCIUM; CALCIUM SIGNALING; GENES, REPORTER; HUMANS; MUSCLE CONTRACTION; MUSCLE, SKELETAL; REPRODUCIBILITY OF RESULTS;

EID: 85003286532     PISSN: None     EISSN: 2050084X     Source Type: Journal    
DOI: 10.7554/eLife.04885     Document Type: Article

References (44)

1. Dambach DM, Uppal H. Improving Risk Assessment. Sci Transl Med. 2012;4(159):159-222.
2. Bhatia SN, Ingber DE. Microfluidic organs-on-chips. Nature biotechnology. 2014;32(8):760-72.
3. Pedersen BK, Febbraio MA. Muscles, exercise and obesity: skeletal muscle as a secretory organ. Nature reviews Endocrinology. 2012;8(8):457-65.
4. von Keutz E, Schluter G. Preclinical safety evaluation of cerivastatin, a novel HMG-CoA reductase inhibitor. The American journal of cardiology. 1998;82(4b):11j-7j.
5. Thompson PD, Clarkson PM, Rosenson RS. An assessment of statin safety by muscle experts. The American journal of cardiology. 2006;97(8a):69c-76c.
6. Blau HM, Webster C. Isolation and characterization of human muscle cells. Proceedings of the National Academy of Sciences of the United States of America. 1981;78(9):5623-7.
7. Guo X, Greene K, Akanda N, Smith A, Stancescu M, Lambert S, et al. In vitro Differentiation of Functional Human Skeletal Myotubes in a Defined System. Biomaterials science. 2014;2(1):131-8.
8. Eberli D, Soker S, Atala A, Yoo JJ. Optimization of human skeletal muscle precursor cell culture and myofiber formation in vitro. Methods (San Diego, Calif). 2009;47(2):98-103.
9. Smith AS, Long CJ, Pirozzi K, Najjar S, McAleer C, Vandenburgh HH, et al. A multiplexed chip-based assay system for investigating the functional development of human skeletal myotubes in vitro. Journal of biotechnology. 2014;185c:15-8.
10. Ciciliot S, Rossi AC, Dyar KA, Blaauw B, Schiaffino S. Muscle type and fiber type specificity in muscle wasting. The international journal of biochemistry & cell biology. 2013;45(10):2191-9.
11. Dennis RG, Kosnik PE, 2nd. Excitability and isometric contractile properties of mammalian skeletal muscle constructs engineered in vitro. In vitro cellular & developmental biology Animal. 2000;36(5):327-35.
12. Huang YC, Dennis RG, Larkin L, Baar K. Rapid formation of functional muscle in vitro using fibrin gels. Journal of applied physiology (Bethesda, Md: 1985). 2005;98(2):706-13.
13. Hinds S, Bian W, Dennis RG, Bursac N. The role of extracellular matrix composition in structure and function of bioengineered skeletal muscle. Biomaterials. 2011;32(14):3575-83.
14. Juhas M, Engelmayr GC, Jr., Fontanella AN, Palmer GM, Bursac N. Biomimetic engineered muscle with capacity for vascular integration and functional maturation in vivo. Proceedings of the National Academy of Sciences of the United States of America. 2014;111(15):5508-13.
15. Vandenburgh H, Shansky J, Benesch-Lee F, Barbata V, Reid J, Thorrez L, et al. Drug-screening platform based on the contractility of tissue-engineered muscle. Muscle & nerve. 2008;37(4):438-47.
16. Lee PH, Vandenburgh HH. Skeletal muscle atrophy in bioengineered skeletal muscle: a new model system. Tissue engineering Part A. 2013;19(19-20):2147-55.
17. Moon du G, Christ G, Stitzel JD, Atala A, Yoo JJ. Cyclic mechanical preconditioning improves engineered muscle contraction. Tissue engineering Part A. 2008;14(4):473-82.
18. Mudera V, Smith AS, Brady MA, Lewis MP. The effect of cell density on the maturation and contractile ability of muscle derived cells in a 3D tissue-engineered skeletal muscle model and determination of the cellular and mechanical stimuli required for the synthesis of a postural phenotype. Journal of cellular physiology. 2010;225(3):646-53.
19. Powell CA, Smiley BL, Mills J, Vandenburgh HH. Mechanical stimulation improves tissue-engineered human skeletal muscle. American journal of physiology Cell physiology. 2002;283(5):C1557-65.
20. Bottinelli R, Reggiani C. Human skeletal muscle fibres: molecular and functional diversity. Progress in biophysics and molecular biology. 2000;73(2-4):195-262.
21. Fuglevand AJ, Macefield VG, Bigland-Ritchie B. Force-frequency and fatigue properties of motor units in muscles that control digits of the human hand. Journal of neurophysiology. 1999;81(4):1718-29.
22. Ham RG, St Clair JA, Webster C, Blau HM. Improved media for normal human muscle satellite cells: serum-free clonal growth and enhanced growth with low serum. In vitro cellular & developmental biology: journal of the Tissue Culture Association. 1988;24(8):833-44.
23. Cheng CS, El-Abd Y, Bui K, Hyun YE, Hughes RH, Kraus WE, et al. Conditions that promote primary human skeletal myoblast culture and muscle differentiation in vitro. American journal of physiology Cell physiology. 2014;306(4):C385-95.
24. Rassier DE, MacIntosh BR, Herzog W. Length dependence of active force production in skeletal muscle. Journal of applied physiology (Bethesda, Md: 1985). 1999;86(5):1445-57.
25. Racca AW, Beck AE, Rao VS, Flint GV, Lundy SD, Born DE, et al. Contractility and kinetics of human fetal and human adult skeletal muscle. The Journal of physiology. 2013;591(Pt 12):3049-61.
26. Cheng CS, Davis BN, Madden L, Bursac N, Truskey GA. Physiology and metabolism of tissue-engineered skeletal muscle. Experimental biology and medicine (Maywood, NJ). 2014.
27. Berchtold MW, Brinkmeier H, Muntener M. Calcium ion in skeletal muscle: its crucial role for muscle function, plasticity, and disease. Physiological reviews. 2000;80(3):1215-65.
28. Chen TW, Wardill TJ, Sun Y, Pulver SR, Renninger SL, Baohan A, et al. Ultrasensitive fluorescent proteins for imaging neuronal activity. Nature. 2013;499(7458):295-300.
29. Salva MZ, Himeda CL, Tai PW, Nishiuchi E, Gregorevic P, Allen JM, et al. Design of tissue-specific regulatory cassettes for high-level rAAV-mediated expression in skeletal and cardiac muscle. Molecular therapy: the journal of the American Society of Gene Therapy. 2007;15(2):320-9.
30. Moulds RF, Denborough MA. A study of the action of caffeine, halothane, potassium chloride and procaine on normal human skeletal muscle. Clinical and experimental pharmacology & physiology. 1974;1(3):197-209.
31. Kalamida D, Poulas K, Avramopoulou V, Fostieri E, Lagoumintzis G, Lazaridis K, et al. Muscle and neuronal nicotinic acetylcholine receptors. Structure, function and pathogenicity. The FEBS journal. 2007;274(15):3799-845.
32. Secher NH, Rube N, Secher O. Effect of tubocurarine on human soleus and gastrocnemius muscles. Acta anaesthesiologica Scandinavica. 1982;26(3):231-4.
33. Dobkin BH. Underappreciated statin-induced myopathic weakness causes disability. Neurorehabilitation and neural repair. 2005;19(3):259-63.
34. Shitara Y, Sugiyama Y. Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: drug-drug interactions and interindividual differences in transporter and metabolic enzyme functions. Pharmacology & therapeutics. 2006;112(1):71-105.
35. Kantola T, Kivisto KT, Neuvonen PJ. Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid. Clinical pharmacology and therapeutics. 1998;63(4):397-402.
36. Shintani T, Klionsky DJ. Autophagy in health and disease: a double-edged sword. Science (New York, NY). 2004;306(5698):990-5.
37. Lee HS, Daniels BH, Salas E, Bollen AW, Debnath J, Margeta M. Clinical utility of LC3 and p62 immunohistochemistry in diagnosis of drug-induced autophagic vacuolar myopathies: a case-control study. PloS one. 2012;7(4):e36221.
38. Burniston JG, Clark WA, Tan LB, Goldspink DF. Dose-dependent separation of the hypertrophic and myotoxic effects of the beta(2)-adrenergic receptor agonist clenbuterol in rat striated muscles. Muscle & nerve. 2006;33(5):655-63.
39. Ryall JG, Lynch GS. The potential and the pitfalls of beta-adrenoceptor agonists for the management of skeletal muscle wasting. Pharmacology & therapeutics. 2008;120(3):219-32.
40. Chen KD, Alway SE. A physiological level of clenbuterol does not prevent atrophy or loss of force in skeletal muscle of old rats. Journal of applied physiology (Bethesda, Md: 1985). 2000;89(2):606-12.
41. Bowes J, Brown AJ, Hamon J, Jarolimek W, Sridhar A, Waldron G, et al. Reducing safety-related drug attrition: the use of in vitro pharmacological profiling. Nat Rev Drug Discov. 2012;11(12):909-22.
42. Juhas M, Bursac N. Roles of adherent myogenic cells and dynamic culture in engineered muscle function and maintenance of satellite cells. Biomaterials. 2014;35(35):9438-46.
43. Kleinstreuer NC, Yang J, Berg EL, Knudsen TB, Richard AM, Martin MT, et al. Phenotypic screening of the ToxCast chemical library to classify toxic and therapeutic mechanisms. Nature biotechnology. 2014;32(6):583-91.
44. Li M, Dickinson CE, Finkelstein EB, Neville CM, Sundback CA. The role of fibroblasts in self-assembled skeletal muscle. Tissue engineering Part A. 2011;17(21-22):2641-50.